4D Molecular Therapeutics Inc (FDMT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
4D Molecular Therapeutics Inc stock (FDMT) is currently trading at $9.18. 4D Molecular Therapeutics Inc PS ratio (Price-to-Sales) is 5.77. Analyst consensus price target for FDMT is $33.25. WallStSmart rates FDMT as Sell.
- FDMT PE ratio analysis and historical PE chart
- FDMT PS ratio (Price-to-Sales) history and trend
- FDMT intrinsic value — DCF, Graham Number, EPV models
- FDMT stock price prediction 2025 2026 2027 2028 2029 2030
- FDMT fair value vs current price
- FDMT insider transactions and insider buying
- Is FDMT undervalued or overvalued?
- 4D Molecular Therapeutics Inc financial analysis — revenue, earnings, cash flow
- FDMT Piotroski F-Score and Altman Z-Score
- FDMT analyst price target and Smart Rating
4D Molecular Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
4D Molecular Therapeutics Inc (FDMT) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, institutional own.. Concerns around return on equity and profit margin. Mixed signals suggest waiting for clearer direction before acting.
4D Molecular Therapeutics Inc (FDMT) Key Strengths (3)
Revenue surging 8509000.00% year-over-year
105.85% of shares held by major funds and institutions
Trading at 1.19x book value, attractively priced
Supporting Valuation Data
4D Molecular Therapeutics Inc (FDMT) Areas to Watch (5)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Premium valuation at 5.8x annual revenue
Small-cap company with higher risk but more growth potential
Decent operational efficiency, solid but not exceptional
Supporting Valuation Data
4D Molecular Therapeutics Inc (FDMT) Detailed Analysis Report
Overall Assessment
This company scores 42/100 in our Smart Analysis, earning a D grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.3/10) while 5 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Price/Book. Valuation metrics including Price/Book (1.19) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 8509000.00%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Price/Sales. Some valuation metrics including Price/Sales (5.77) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -27.60%, Operating Margin at 17.40%, Profit Margin at -164.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -27.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 8509000.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
FDMT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
FDMT's Price-to-Sales ratio of 5.77x trades at a deep discount to its historical average of 1246.24x (0th percentile). The current valuation is 100% below its historical high of 8492.14x set in Aug 2025, and 0% above its historical low of 5.77x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~5004.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for 4D Molecular Therapeutics Inc (FDMT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
4D Molecular Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 85M with 8509000% growth year-over-year. The company is currently unprofitable, posting a -164.4% profit margin.
Key Findings
Revenue growing at 8509000% YoY, reaching 85M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 28M in free cash flow and 29M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -164.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can 4D Molecular Therapeutics Inc maintain 8509000%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 3.01, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact 4D Molecular Therapeutics Inc.
Bottom Line
4D Molecular Therapeutics Inc is a high-conviction growth story with revenue accelerating at 8509000% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -164.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About 4D Molecular Therapeutics Inc(FDMT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California.